Madrigal Pharmaceuticals (MDGL) Notes Payables (2015)

Madrigal Pharmaceuticals (MDGL) reported Notes Payables of $48.6 million for Q4 2015.

Madrigal Pharmaceuticals (MDGL) Notes Payables (2015) Analysis & Trends

Madrigal Pharmaceuticals (MDGL) has 1 years of Notes Payables data on file, last reported at $48.6 million in Q4 2015.

  • Notes Payables for Q4 2015 came in at $48.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2015 was $48.6 million (changed N/A YoY), and the FY2015 annual result was $48.6 million, changed N/A from the prior year.
  • Notes Payables was little changed at $48.6 million in Q4 2015 per MDGL's latest filing.
  • Over five years, Notes Payables peaked at $48.6 million in Q4 2015 and troughed at $48.6 million in Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Madrigal Pharmaceuticals 14.67 Bn 14.44 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2015 48.60 Mn